Neurally Acting Anti-Migraine Agents

Neurally Acting Anti-Migraine Agents (NAAMAs) are a new class of drugs that provide safe, effective migraine relief without vasoconstriction. Lasmiditan is a first-in-class therapy that selectively targets 5-HT_1F receptors expressed in the trigeminal pathway.

Localization of 5-HT Receptors in Migraine Pathways

Studies have demonstrated the following:

• Vasoconstriction is not necessary to relieve migraine headache symptoms.
  Shepheard et al 1999, Bouchelet et al 2000, Goldstein et al 2001
• Selective 5-HT_1F agonists block pain transmission without causing vasoconstriction.
  Mitsikostas, et al 1999, Shepheard et al 1999
• Lasmiditan is a selective 5-HT_1F
  COL-144 Preclinical profile of a selective 5HT_1F receptor agonist for migraine
• Selective 5-HT_1F agonists, including lasmiditan, have successfully treated migraine patients.
  Nelson et al, 2010, Ferrari et al, 2010, Editorial by Olesen, 2010, Goadsby et al 2002